Eisai Files for Approval of Alzheimer’s Drug in Japan
![](https://japannews.yomiuri.co.jp/wp-content/uploads/2023/01/20230116-OYT1I50036-1.jpg)
Alzheimer’s drug lecanemab
10:39 JST, January 16, 2023
Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated approval in the United States.
The drug, developed in partnership with Biogen Inc BIIB.O, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
The company’s application is based on results from a late-stage study in which the drug was shown to reduce the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.
"Business" POPULAR ARTICLE
-
Japanese Companies Increasing Efforts to Hire Foreign Students; Firms, Local Governments Help Them Acquire Skills to Find Jobs in Japan
-
Japan’s Casio to Launch Durable Clothing Range Inspired by G-Shock Brand; Company to Debut Durable T-Shirt in Late August
-
Insufficient Rice Supply Hits Japan; Sever Heat, Rising Demand from Inbound Tourist Among Factors
-
Japanese Firm Hitachi to Release Vacuum Using AR That Turns Cleaning Into a Game; Stressful Cleaning May Become More Enjoyable
-
Sony to Open New Brand Complex Building in Tokyo’s Ginza Next Year; ‘Ginza Sony Park’ to Serve as Brand Hub for Entertainment Businesses
JN ACCESS RANKING